Trial SWOG-S1937


A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Sarmad Sadeghi, M.D.
Other Trial Staff:  Aaron Mejia, Coordinator, Cheryl Kefauver, R.N., Monica Flores, D.M., Lagrimas Ilagan, D.M., Mary Ordaz, D.M., Roberto Tejada, Coordinator, Shamim Jhimlee, Coordinator, Honorina Enright, D.M., Amanda Luna, Coordinator, Niranjan Bhatt, D.M., Bartolo Santos, Coordinator, Aubrianne Cho, Coordinator, Thomas Elimihele, D.M., Viviana Moreno, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.